

CTLIMM.001CP1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kundig, et al.

Appl. No. : 09/380,534

Filed : September 1, 1999

For : A METHOD OF INDUCING A
CTL RESPONSE

Examiner : Michael Hayes

) Group Art Unit 3700

) I hereby certify that this correspondence and all
) marked attachments are being deposited with
) the United States Postal Service as first-class
) mail in an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
) 20231, on

November 13, 2000

(Date)

Dale C. Hunt, Reg. No. 41,857

Preliminary AmendmentAssistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination and prior to calculation of the filing fee, please amend the above-identified patent application as follows:

IN THE CLAIMS

Kindly amend claims 19-21 as follows:

19. (Amended) [A] The method according to Claim 17, wherein the antigen is selected from the group consisting of MART-1/MelanA (MART-1), gp100 (Pmel-17), tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15(58), CEA p53, Ras, HER-2/neu, BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, EBVA, (HPV) antigens E6 and E7, TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, H-ras, β -Catenin, CDK4, Mum-1, p15, p16.

20. (Amended) [A] The method according to Claim 4, wherein a cytokine that is capable of enhancing the CTL response is delivered and/or maintained along with the antigen.